Reports Q1 revenue $9.17M, consensus $9.04M. “Our strong first quarter performance reflects the growing impact of our PEDD platform across a variety of solid tumor indications,” said Mary Szela, President and CEO of TriSalus. “With the decision to partner Nelitolimod development following completion of the Phase 1 trials, and the expansion of our TriNav portfolio for a wide range of new applications, we are better positioned than ever to execute our long-term strategy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences reports preliminary Q1 revenue $9.2M, consensus $9.04M
- TriSalus Life Sciences to sell 5.5M shares at $4.00 in private placement
- TriSalus Life Sciences Announces $22M Private Placement
- TriSalus Life Sciences files to sell 252K shares of common stock for holders
- TriSalus Life Sciences files to sell 91,263 shares of common stock for holders